摘要: … topoisomerase I (topo I) inhibitors that are under clinical development. To date, all of the topo I … -8951f), on oral formulations, and on non-campto thecin topoisomerase I inhibitors. The …
annalsofoncology.org
oup.com
oxfordjournals.org
sci-hub.se 参考文章(140)
Allan Y. Chen, Leroy F. Liu, Mechanisms of resistance to topoisomerase inhibitors Cancer treatment and research. ,vol. 73, pp. 263- 281 ,(1994) , 10.1007/978-1-4615-2632-2_13
O S Selawry, F M Muggia, M H Cohen, P J Creaven, H H Hansen, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer chemotherapy reports. ,vol. 56, pp. 515- 521 ,(1972)
A Wakui, T Taguchi, Y Sakata, M Yoshino, Y Shimada, K Futatsuki, I Nakao, N Ogawa, M Kambe, [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 1033- 1038 ,(1994)
Barbara G. Lubejko, Louise B. Grochow, David S. Ettinger, Susan E. Sartorius, Ross C. Donehower, Eric K. Rowinsky, Michael K. Rock, Tian-Ling Chen, Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks Cancer Research. ,vol. 54, pp. 427- 436 ,(1994)
Robert S. Witte, Judith Manola, Patrick A. Burch, Timothy Kuzel, Eric L. Weinshel, Patrick J. Loehrer, Sr., Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial Investigational New Drugs. ,vol. 16, pp. 191- 195 ,(1998) , 10.1023/A:1006159525793
Mary K. Danks, Raquel C. Marion, David O. Whipple, Katherine E. Garrett, Subcellular Redistribution of DNA Topoisomerase I in Anaplastic Astrocytoma Cells Treated with Topotecan Cancer Research. ,vol. 56, pp. 1664- 1673 ,(1996)
Laurent P. Rivory, Marc Vuilhorgne, Alain Commerçon, Susan M. Pond, Jacques Robert, Marie-Christine Haaz, Jean-François Riou, Serge Sable, Identification and Properties of a Major Plasma Metabolite of Irinotecan (CPT-11) Isolated from the Plasma of Patients Cancer Research. ,vol. 56, pp. 3689- 3694 ,(1996)
N. Fujii, Y. Yamashita, Y. Saitoh, H. Nakano, Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein Journal of Biological Chemistry. ,vol. 268, pp. 13160- 13165 ,(1993) , 10.1016/S0021-9258(19)38632-6
Julie K. Horton, Erasmus Schneider, Kenneth H. Cowan, Chih-Hsin J. Yang, Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations Cancer Research. ,vol. 55, pp. 4004- 4009 ,(1995)
C.J. Li, L Averboukh, A.B. Pardee, beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. Journal of Biological Chemistry. ,vol. 268, pp. 22463- 22468 ,(1993) , 10.1016/S0021-9258(18)41552-9